Side effects of high-dose intravenous immunoglobulins
- PMID: 9331514
- DOI: 10.1097/00002826-199710000-00002
Side effects of high-dose intravenous immunoglobulins
Abstract
Intravenous immunoglobulins (IVIgs) are used increasingly as therapy for neuroimmunologic and other autoimmune diseases. With broader use, the number of reported side effects also is growing. Here we review the literature on adverse reactions reported after administration of i.v.Igs. Despite a few recent reports about a high frequency of complications of IVIgs, by and large they can be considered as safe. Mild and self-limited side effects may occur, but severe complications are rare and often associated with other risk factors for these complications. A careful screening for preexisting illnesses and monitoring of some laboratory parameters can minimize the risks of IVIg therapy.
Similar articles
-
The safety profile of home infusion of intravenous immunoglobulin in patients with neuroimmunologic disorders.J Clin Neuromuscul Dis. 2011 Jun;12 Suppl 4:S1-10. doi: 10.1097/CND.0b013e3182212589. J Clin Neuromuscul Dis. 2011. PMID: 22361589 Review.
-
High-dose intravenous immunoglobulins for the treatment of dermatological autoimmune diseases.J Dtsch Dermatol Ges. 2017 Dec;15(12):1211-1226. doi: 10.1111/ddg.13389. J Dtsch Dermatol Ges. 2017. PMID: 29228499 Review.
-
Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion: report of 4 cases and review of the literature.Arch Dermatol. 2006 Feb;142(2):213-7. doi: 10.1001/archderm.142.2.213. Arch Dermatol. 2006. PMID: 16490849
-
Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies.Neurology. 2002 Dec 24;59(12 Suppl 6):S33-40. doi: 10.1212/wnl.59.12_suppl_6.s33. Neurology. 2002. PMID: 12499469 Review.
-
Critical decisions in selecting an intravenous immunoglobulin product.J Infus Nurs. 2005 Nov-Dec;28(6):366-74. doi: 10.1097/00129804-200511000-00003. J Infus Nurs. 2005. PMID: 16304494
Cited by
-
Increased risk of adverse events when changing intravenous immunoglobulin preparations.Clin Exp Immunol. 2004 Apr;136(1):111-3. doi: 10.1111/j.1365-2249.2004.02412.x. Clin Exp Immunol. 2004. PMID: 15030521 Free PMC article.
-
[Intravenous immunoglobulins in multiple sclerosis. An update].Nervenarzt. 2009 Aug;80(8):918-28. doi: 10.1007/s00115-009-2669-5. Nervenarzt. 2009. PMID: 19662451 Review. German.
-
Intravenous immunoglobulin therapy for acquired coagulation inhibitors: a critical review.Int J Hematol. 2007 May;85(4):287-93. doi: 10.1532/IJH97.06222. Int J Hematol. 2007. PMID: 17483070 Review.
-
Adverse effects of treatment with intravenous immunoglobulins for neurological diseases.J Neurol. 2006 Sep;253 Suppl 5:V75-9. doi: 10.1007/s00415-006-5013-z. J Neurol. 2006. PMID: 16998759 Review.
-
Efficacy and safety of ClairYg®, a ready-to-use intravenous immunoglobulin, in adult patients with primary immune thrombocytopenia.Am J Blood Res. 2017 Jan 15;7(1):1-9. eCollection 2017. Am J Blood Res. 2017. PMID: 28203488 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources